COVID-19 to Drive Demand for Extracorporeal Membrane Oxygenation Devices

The global extracorporeal membrane oxygenation (ECMO) devices market will likely benefit from the COVID-19 pandemic over the next few years as healthcare infrastructure investments increase and patient preference and awareness of ECMO devices rise, according to GlobalData.

The pandemic has highlighted the need for advanced life support systems to treat critically ill patients with severe respiratory failure. According to GlobalData, the top revenue grossing sub-segments for ECMO include blood pumps, integrated units, and oxygenators, which together accounted for approximately 80% of the total market revenue in 2022. 
 
Getinge AB is leading in integrated units, which is a second largest sub-segment overall. Getinge AB is leading in every region except the Northeast.
 
“The ECMO market is thriving with increasing prevalence of respiratory and cardiac failure, and technological advancements in ECMO devices such as improved portability, increased automation, and enhanced monitoring capabilities,” GlobalData Medical Device Analyst Kamilla Kan said. “The market is characterized by intense competition, with companies focusing on product development, strategic collaborations, and mergers and acquisitions to gain a competitive edge. As the market continues to evolve, ECMO will likely become an increasingly important part of the healthcare landscape, providing life-saving treatment options for critically ill patients.”